Bio-Path Holdings Files 8-K
Ticker: BPTH · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings, Inc. (BPTH) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
Related Tickers: BPTH
TL;DR
BPTH filed a routine 8-K, no major news.
AI Summary
Bio-Path Holdings, Inc. filed an 8-K on June 14, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Bio-Path Holdings, Inc. is adhering to its reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material events or financial information that would inherently increase risk.
Key Players & Entities
- BIO-PATH HOLDINGS, INC. (company) — Registrant
- 0001558370-24-009170 (filing_id) — Accession Number
- June 14, 2024 (date) — Report Date
- Delaware (jurisdiction) — State of Incorporation
- 77401 (zip_code) — Business Address Zip
FAQ
What is the primary purpose of this 8-K filing for Bio-Path Holdings, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on June 14, 2024.
What is the Commission File Number for Bio-Path Holdings, Inc.?
The Commission File Number for Bio-Path Holdings, Inc. is 001-36333.
In which state is Bio-Path Holdings, Inc. incorporated?
Bio-Path Holdings, Inc. is incorporated in Delaware.
What is the business address of Bio-Path Holdings, Inc. as listed in the filing?
The business address is 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-06-14 07:18:17
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
Filing Documents
- bpth-20240614x8k.htm (8-K) — 38KB
- bpth-20240614xex99d1.htm (EX-99.1) — 17KB
- bpth-20240614xex99d1001.jpg (GRAPHIC) — 11KB
- 0001558370-24-009170.txt ( ) — 193KB
- bpth-20240614.xsd (EX-101.SCH) — 3KB
- bpth-20240614_lab.xml (EX-101.LAB) — 16KB
- bpth-20240614_pre.xml (EX-101.PRE) — 10KB
- bpth-20240614x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 14, 2024, Bio-Path Holdings, Inc. (the "Company") issued a press release titled, "Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress." A copy of such press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated June 14, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: June 14, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer